ClinicalTrials.gg
TerminatedNCT00282581Updated Jan 22, 2014

Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive

A Phase 1 interventional study of MVA Smallpox Vaccine in HIV Infections and Smallpox, sponsored by Sanofi Pasteur, a Sanofi Company. Terminated at 6 sites in United States. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-01-22.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 1, Interventional, and Prevention

Why this study was terminated
Senior managemnt decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 2,803 studies in HIV Infections with a site in United States — 84 open to participants now, 141 under way, 11 of them phase 3. HIV Infections · United States.

Enrollment
2,115th of 2,151
2 · median 60
Started
2006
with 108 others
Phase 1
671 of 2,803
10 open now
Registered
1,586th of 2,803
by date

Among the 2,803 studies in HIV Infections with a site in United States, this one is the 2,115th largest by enrollment of the 2,151 interventional ones that give a count, is one of 109 that started in 2006, is one of 671 in phase 1, and was the 1,586th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

84 of the 2,803 studies in HIV Infections with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,803 studies in HIV Infections with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and immunogenicity of two MVA smallpox vaccine injections in healthy adults that are 18-35 years of age with HIV infection

Read the detailed description

This is a multi-center study 90 HIV-seropositive subjects. There will be an injection of MVA smallpox vaccine or placebo on day 0 and day 28.

Subjects will be enrolled and vaccinated in two cohorts according to CD4 cell count levels and number of subjects vaccinated. Excluding the screening period, the study duration will be approximately 56 days with a follow up safety visit at study day 148 and a telephone health status interview at study day 208.

03

Conditions studied

  • HIV Infections
  • Smallpox

Keywords

  • HIV
  • Smallpox
  • MVA
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults at least 18 years old and who were born after 1971 who have never had a smallpox vaccination or exposure to a vaccinia-containing product
  • Subjects must test positive for infection
  • Subjects must be in good general health except for HIV infection, including no AIDS-defining illnesses.
  • Female Subjects must not be pregnant or lactating, and all subjects must agree to practice
  • subjects must be clinically stable for 6 months prior to study enrollment.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a known or suspected history of immunodeficiency (with the exception of infection)
  • Subjects with history or prior exposure to a vaccinia-containing product
  • subjects with current radiation treatment or use of or antineoplastic drugs (with exceptions)
  • Subjects with concomitant illnesses associated with impairment of immunologic function.
  • subjects with dementia
  • Subjects with .
  • Subjects with a known history of Cardiac disease, or who have risk factors for ischemic coronary disease, or other abnormalities
  • Current or past history of eczema
  • known allergies to any component of MVA, including eggs or egg products, or allergies to blood products
  • females must not be pregnant and using approved .
  • Morbid obesity
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
2 participants (actual)

Study arms

  • Placebo comparator
    placebo

    Biological: MVA Smallpox Vaccine

Interventions

  • BiologicalMVA Smallpox Vaccine

    0.5mL of MVA3000 Smallpox Vaccine, 2 doses, separated by 28 days.

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. Safety

    Time frame: Study Completion

Secondary outcomes

  1. Immunogenicity

    Time frame: Study Completion

07

Study locations

6 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-2050, United States
  • AltaMed Health Services Corporation
    Los Angeles, California 90022, United States
  • Quest Clinical Research
    San Francisco, California 94115, United States
  • University of Miami AIDS Clinical Research Unit
    Miami, Florida 33136, United States
  • University of Miami School of Medicine
    Miami, Florida 33136, United States
  • University of Hawaii
    Honolulu, Hawaii 96816, United States
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2006
First posted
Jan 27, 2006
Start
Oct 2006
Primary completionActual
Jul 2007
CompletionActual
Jul 2007
Last update
Jan 22, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00282581
Responsible party
Sponsor
First posted
Jan 27, 2006
Start date
Oct 2006
Primary completion
Jul 2007
Completion
Jul 2007
Last update
Jan 22, 2014

Study contacts

Margaret Fischl, MD
principal investigator · University of Miami AIDS clinical research unit
Rafael E Campo, MD
principal investigator · University of Miami
Cecilia Shikuma, MD
principal investigator · University of Hawaii- Honolulu
Daniel Pearce, DO
principal investigator · AltaMed Health Services, Los Angeles
Jacob Lalezari, MD
principal investigator · Quest Clinical Research, San Francisco
Scott D Parker, MD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion